N/A N=314

Primary Immunodeficiency in Kuwait

Primary Immune Deficiency Disorder

Bottom Line

View on ClinicalTrials.gov: NCT03618147 ↗

Enrolled (actual)

314

Serious AEs

—

Results posted

Sep 2019

Primary outcome: Primary: Number of Participants With Different Epidemiological Features — 287; 100; 68; 56 patients

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Kuwait Society for Allergy and Clinical Immunology
Primary completion: May 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Different Epidemiological Features	287; 100; 68; 56; 47; 20	—
PRIMARY Number of Overall and New Cases of PID Per 100,000 Kuwaitis	20; 25	—

Summary

* Background/Rationale: Epidemiological data about Primary Immunodeficiency Disorders (PIDD) in Kuwait is needed to better understand peculiarities and to compare them with other regions and ethnicity. * Study hypothesis: PIDD is relatively common in Kuwait compared to populations from different geographic areas. The distribution of PIDD in Kuwait is different from other geographic areas with more severe forms being more frequent. * Brief inclusion and exclusion criteria of study participants: PIDD patients presented at different clinics/hospital in Kuwait. Patients with secondary immunodeficiencies (drug induced, virus induced, and immunodeficiency associated with metabolic disorders... ect), will be excluded * Estimated sample size of the study: All patients who were registered in KNPIDR since 2004 will be included in the study along with the new patients who will be recruited during the study period. * Primary objectives: * Determine the prevalence and frequency of different PIDD in Kuwait * Identify clinical presentation patterns for PIDD in Kuwait * Identify natural history of PIDD in Kuwait * Help to asses epidemiology of PIDD in Kuwait * Determine particularities about PIDD affecting the population in Kuwait * Determine the health impact of PIDD in Kuwait * Development of strategies to improve the care and the quality of life of patients with PIDD

Eligibility Criteria

Inclusion Criteria

PIDD patients presented at different clinics/hospital in Kuwait
Exclusion Criteria: Patients with secondary immunodeficiencies (drug induced, virus induced, and immunodeficiency associated with metabolic disorders... ect)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03618147). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.